Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Cash Flow (2021 - 2025)

Historic Net Cash Flow for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to -$2.4 million.

  • InMed Pharmaceuticals' Net Cash Flow fell 982.73% to -$2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.5 million, marking a year-over-year increase of 15781.07%. This contributed to the annual value of $4.5 million for FY2025, which is 29241.52% up from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Net Cash Flow is -$2.4 million, which was down 982.73% from -$1.7 million recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Net Cash Flow ranged from a high of $8.0 million in Q3 2021 and a low of -$5.4 million during Q1 2022
  • In the last 5 years, InMed Pharmaceuticals' Net Cash Flow had a median value of -$1.4 million in 2024 and averaged -$252946.8.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Net Cash Flow crashed by 34826.16% in 2023, and later soared by 72158.6% in 2025.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Net Cash Flow stood at -$4.1 million in 2021, then surged by 164.03% to $2.6 million in 2022, then tumbled by 171.02% to -$1.8 million in 2023, then decreased by 17.07% to -$2.2 million in 2024, then decreased by 9.83% to -$2.4 million in 2025.
  • Its Net Cash Flow was -$2.4 million in Q4 2025, compared to -$1.7 million in Q3 2025 and $6.4 million in Q2 2025.